Dalton Pharma News

Dalton Pharma Services Receives Compliant Rating from Health Canada

TORONTO: (Jun 6, 2018) Dalton Pharma Services is proud to announce that, subsequent to a Good Manufacturing Practices (GMP) inspection conducted at Dalton’s GMP manufacturing facility during March 2018, it has successfully received a ‘Compliant’ rating from the Health Products and Food Branch Inspectorate of Health Canada.

This inspection covered the scope of sterile and non-sterile drug products, Active Pharmaceutical Ingredients (API), raw material controls, existing quality management systems, documentation, equipment, processes and engineering. The compliant rating means that the company has successfully demonstrated these activities are in compliance with the high standards of the Canadian Food and Drugs Act and its associated regulations.

“In the wake of recent serious quality issues in the Contract Manufacturing Industry noted by regulators, this successful audit by Health Canada reaffirms Dalton`s commitment to providing products and services of the highest quality and standards to our clients,” said Peter Pekos, President and CEO.

“We believe this positive audit is a direct result of having Quality and Compliance as cornerstones for our business and successfully demonstrates that our facilities and activities are in compliance with the high standards of Canadian Food and Drugs Act and associated regulations. Dalton will strive to consistently provide the highest quality products and services at all times.” said Natalie Lazarowych, Director of Quality. 

About Dalton Pharma Services:

Dalton Pharma Services is a leading North American cGMP pharmaceutical organization providing integrated drug discovery, development and manufacturing services. We are FDA registered and Health Canada approved and bring over 30 years of experience to every project. We deliver fully integrated solutions with an emphasis on speed, flexibility and quality. Our integrated services (drug discovery, formulation and process development, custom synthesis, cGMP sterile fill/finish of liquids and powders, cGMP API manufacturing and/or dosage form manufacturing and Accelerated Stability Testing) all at one location helps us to be adaptable, flexible and cost-effective.

To learn more about our history and capabilities, please visit https://www.dalton.com.
Peter Pekos 
President & CEO 
Dalton Pharma Services 
349 Wildcat Road 
Toronto, Ontario 
Tel: 416-661-2102